GlassScriptPhysician profile
Roberto Morales
NPI 1134666290
$5,486.81
in general payments reported to CMS, 2019-2025
26 companies · $2,634 in 2025
The $2,634 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $482 · 2022: $208 · 2023: $392 · 2024: $1,771 · 2025: $2,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,796.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $2,979.42 | 2024-2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $436.06 | 2021-2024 | Xarelto |
| Cvrx, INC. | $294.23 | 2024-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $279.25 | 2021-2025 | Farxiga |
| Abiomed | $210.29 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $181.74 | 2024 | |
| Amgen INC. | $160.19 | 2021-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $150.59 | 2024 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $150.32 | 2024 | Verquvo |
| Sanofi-Aventis U.S. LLC | $124.97 | 2022 | |
| Penumbra, INC. | $103.77 | 2025 | Indigo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $78.67 | 2022-2023 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $41.04 | 2024 | Arcalyst |
| Atricure, INC. | $40.69 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Cordis US Corp. | $40.01 | 2024 | Mynx Venous Vcd |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.75 | 2021 | |
| W. L. Gore & Associates, INC. | $27.97 | 2021-2023 | Gore Viabahn Endoprosthesis With Heparin |
| Otsuka America Pharmaceutical, INC. | $23.85 | 2025 | Abilify Asimtufii |
| Abbvie INC. | $20.77 | 2021 | |
| Novo Nordisk INC | $18.84 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.52 | 2021 | |
| Cardiva Medical, INC. | $16.89 | 2025 | Optowire |
| Vivus LLC | $16.42 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.33 | 2021 | |
| Daiichi Sankyo INC. | $13.19 | 2021 | |
| Esperion Therapeutics, INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.